Halozyme Therapeutics Earnings: Here’s Why Investors are Ambivalent Now
Halozyme Therapeutics, Inc. (NASDAQ:HALO) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
Halozyme Therapeutics, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.17 in the quarter versus EPS of $-0.14 in the year-earlier quarter.
Revenue: Rose 59.01% to $11.83 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Halozyme Therapeutics, Inc. reported adjusted EPS loss of $0.17 per share. By that measure, the company missed the mean analyst estimate of $-0.15. It beat the average revenue estimate of $7.05 million.
Quoting Management: “With the potential for 3 new product launches over the next 12 months and continued progress on the Hylenex® brand, I am pleased with the steps we are making towards our near term revenue drivers,” said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. “Moreover, over the next 8 weeks, we will present a first-look at clinical data from our innovative pipeline products, PEGPH20 and HTI-501.”
Key Stats (on next page)…
Revenue decreased 45.71% from $21.79 million in the previous quarter. EPS increased to $-0.17 in the quarter versus EPS of $-0.04 in the previous quarter.
Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.13 to a loss $0.12. For the current year, the average estimate has moved down from a loss of $0.54 to a loss of $0.55 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)